GlassScriptPhysician profile
Andrew H Rosenstein
NPI 1275615486
$13,811.73
in general payments reported to CMS, 2019-2025
32 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,320 · 2020: $2,647 · 2021: $809 · 2022: $988 · 2023: $1,627 · 2024: $779 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.27 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,670.35 | 2019-2025 | Rinvoq, Mavyret, Viberzi |
| Janssen Biotech, INC. | $1,182.86 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $552.86 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Braintree Laboratories, INC. | $497.33 | 2019-2024 | Suflave, Sutab |
| Celgene Corporation | $461.69 | 2021-2024 | Zeposia |
| Pfizer INC. | $340.88 | 2019-2025 | |
| Horizon Therapeutics Plc | $239.10 | 2019-2023 | Krystexxa |
| Allergan, INC. | $209.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.28 | 2019-2025 | Xifaxan |
| Amgen INC. | $176.74 | 2023-2025 | Krystexxa, Avsola, Amjevita |
| Ardelyx, INC. | $164.03 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $124.75 | 2021-2023 | |
| Genzyme Corporation | $113.12 | 2022-2025 | |
| Gilead Sciences, INC. | $112.61 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $96.53 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $91.84 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $84.77 | 2019-2023 | Ocaliva |
| Qol Medical, LLC | $81.87 | 2019-2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $60.51 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $55.27 | 2019-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $39.02 | 2023 | Rebyota |
| Romark Laboratories, Lc | $36.17 | 2019-2020 | |
| Tersera Therapeutics LLC | $31.13 | 2024 | Xermelo |
| Madrigal Pharmaceuticals | $27.99 | 2025 | Rezdiffra |
| Olympus America INC. | $27.79 | 2019-2023 | Endoclot Phs |
| Laborie Medical Technologies Corp. | $25.19 | 2025 | |
| Caris Mpi, INC. | $24.81 | 2025 | Mi Cancer Seek |
| Fresenius Kabi USA, LLC | $21.89 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.22 | 2023 | Cyltezo |
| Capsovision, INC. | $16.99 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $16.37 | 2023 | Dificid |
| Concordia Pharmaceuticals INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rosenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.